Frequency of FLT3 ITD and FLT3 TKD Mutations in Multiple Myeloma Patients (A Case Control Study)

Authors

  • Hossein Rahimi
  • Mohammad Hadi Sadeghian
  • Mohammad Mehdi Kooshyar
  • Mohammad Reza Keramati
  • Sepideh Shakeri
  • Seyyede Fatemeh Shams
Abstract:

Background and Aims: Multiple myeloma is a malignant proliferation of plasma cells derived from a single clone. The tumor, its products and the host response lead to organ damages. Some factors that are responsible in its pathogenesis are recognized. As FMS like Tyrosine Kinase 3 receptor (FLT3) mutation has been proved as a determining factor in leukemic patients the goal of this study was to find association of FLT3 internal tandem duplication (ITD) and FLT3 tyrosine kinase domain (TKD), mutations with multiple myeloma. Materials and Methods: This case-control study was conducted on 60 paraffin-embedded bone marrow biopsies (30 multiple myeloma and 30 normal bone marrow specimens) in the pathology departments of Ghaem and Imam Reza hospitals in Mashhad. After sections preparation, DNA was extracted and two PCR reactions were set up for detection of FLT3/ ITD and FLT3/TKD mutations. Results: The Mean age of samples was 64±10 years. No FLT3 mutations were detected in multiple myeloma patients. Conclusions: Our findings showed that FLT3 mutations occurrence seem unusual in multiple myeloma.

Upgrade to premium to download articles

Sign up to access the full text

Already have an account?login

similar resources

SRC is a signaling mediator in FLT3-ITD- but not in FLT3-TKD-positive AML.

Mutations of Fms-like tyrosine kinase 3 (FLT3) are among the most frequently detected molecular abnormalities in AML patients. Internal tandem duplications (ITDs) are found in approximately 25% and point mutations within the second tyrosine kinase domain (TKD) in approximately 7% of AML patients. Patients carrying the FLT3-ITD but not the FLT3-TKD mutation have a significantly worse prognosis. ...

full text

MYELOID NEOPLASIA SRC is a signaling mediator in FLT3-ITD– but not in FLT3-TKD–positive AML

1Department of Internal Medicine III, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; 2Experimental Clinical Chemistry, Wallenberg Laboratory, Department of Laboratory Medicine, Lund University, Skåne University Hospital, Malmö, Sweden; and 3Department of Internal Medicine III, Laboratory of Leukemia Diagnostics, Ludwig-Maximilians-University-Campus Grosshadern, Munic...

full text

Individualized Treatment Strategy with Small-Molecular Inhibitors in Acute Myeloid Leukemia with Concurrent FLT3-ITD and FLT3-TKD Mutation

Individualized Treatment Strategy with Small-Molecular Inhibitors in Acute Myeloid Leukemia with Concurrent FLT3-ITD and FLT3-TKD Mutation Harald Polzer1-4*, Hanna Janke1,2, Stephanie Schneider1, Wolfgang Hiddemann1-4, Marion Subklewe1 and Karsten Spiekermann1-4 1Department of Internal Medicine III, University Hospital Großhadern, Ludwig-Maximilians-University Munich, Germany 2Clinical Cooperat...

full text

AML-associated Flt3 kinase domain mutations show signal transduction differences compared with Flt3 ITD mutations.

Activating mutations of Flt3 are found in approximately one third of patients with acute myeloid leukemia (AML) and are an attractive drug target. Two classes of Flt3 mutations occur: internal tandem duplications (ITDs) in the juxtamembrane and point mutations in the tyrosine kinase domain (TKD). We and others have shown that Flt3-ITD induced aberrant signaling including strong activation of si...

full text

Absence of FLT3 mutations in Iranian adult T-cell leukemia/lymphoma patients

Background: Adult T cell leukemia lymphoma (ATLL) is a rare disease, significantly linked to the infection by the human T-cell lymphotropic virus 1(HTLV-1). ATLL is typically preceded by decades of clinical latency during which infected cells accumulate selectable traits leading to a malignant transformation. Amongst all the HTLV-1 infected carriers only about 3-5% will develop ATLL. Despite th...

full text

Dual inhibition of AKT/FLT3-ITD by A674563 overcomes FLT3 ligand-induced drug resistance in FLT3-ITD positive AML

The FLT3-ITD mutation is one of the most prevalent oncogenic mutations in AML. Several FLT3 kinase inhibitors have shown impressive activity in clinical evaluation, however clinical responses are usually transient and clinical effects are rapidly lost due to drug resistance. One of the resistance mechanisms in the AML refractory patients involves FLT3-ligand induced reactivation of AKT and/or E...

full text

My Resources

Save resource for easier access later

Save to my library Already added to my library

{@ msg_add @}


Journal title

volume 2  issue 1

pages  34- 40

publication date 2015-05

By following a journal you will be notified via email when a new issue of this journal is published.

Keywords

Hosted on Doprax cloud platform doprax.com

copyright © 2015-2023